Dr Berger asked the panel how both the June 2013 Supreme Court decision and the Angelina Jolie disclosure impacted genetic testing and counseling. After the Supreme Court's decision there was an influx of inexpensive and more comprehensive genetic tests available.
Dr Berger asked the panel how both the June 2013 Supreme Court decision and the Angelina Jolie disclosure impacted genetic testing and counseling. After the Supreme Court’s decision there was an influx of inexpensive and more comprehensive genetic tests available. “In my view, having also been in the filed for 18 years, the entire playing field changed very, very quickly,” said Ms Matloff. “We suddenly had all of these options and we could order a lot more testing for either less money or certainly the same amount of money we were paying for BRCA analysis from Myriad, and I think this is a good and bad thing.”
Dr Brawley said that since Angelina Jolie’s disclosure, the American Cancer Society has had more inquiries regarding BRCA testing, but only BRCA testing alone. He also notes the increase of women choosing to have bilateral mastectomies even though that is not the right decision for everyone. “Many of the women who chose to get a bilateral mastectomy or are choosing to get a bilateral mastectomy, if they were to sit back, think, and understand everything about it they might chose a different method of trying to prevent breast cancer,” said Dr Brawley.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen